Alan Lacy - Bristol Myers Independent Director
Director
Mr. Alan J. Lacy is Independent Director of BristolMyers Squibb Company. Mr. Lacy served as the NonExecutive Chairman of Dave Buster Entertainment Inc. from 2014 to 2017. He served as the Chairman and Chief Executive Officer of Sears, Roebuck and Co. and the Vice Chairman and Chief Executive Officer of its successor, Sears Holdings Corporationrationration, from 2000 to 2005. Mr. Lacy also served as Vice Chairman of Sears Holdings Corporation from 2005 to 2006. More recently, Mr. Lacy served as Senior Advisor to Oak Hill Capital Partners, L.P., a private equity investment firm, from 2007 to 2014. He is a Trustee of Fidelity Funds and the California Chapter of The Nature Conservancy. Mr. Lacy is a Director of the Center for Advanced Study in the Behavioral Sciences at Stanford University. since 2008.
Age | 64 |
Tenure | 16 years |
Phone | 212-546-4000 |
Web | http://www.bms.com |
Similar Executives
Showing other executives | DIRECTOR Age | ||
Christoph Franz | Roche Holding Ltd | 58 | |
Hironobu Furuta | Daiichi Sankyo | N/A | |
Yoshikazu Fukuchi | Daiichi Sankyo | N/A | |
Yuichi Murakami | Astellas Pharma | N/A | |
Nazneen Rahman | AstraZeneca PLC ADR | N/A | |
Noriyuki Uematsu | Astellas Pharma | 57 | |
Tadashi Hara | Astellas Pharma | N/A | |
William Anderson | Chugai Pharmaceutical Co | 51 | |
Peter Voser | Roche Holding Ltd | 59 | |
Christoph Franz | Roche Holding AG | 58 | |
Nancy Andrews | Novartis AG ADR | 63 | |
Hideyuki Hirano | Daiichi Sankyo | N/A | |
Koichi Akahane | Daiichi Sankyo | N/A | |
Bernard Poussot | Roche Holding Ltd | 66 | |
Yuki Sato | Daiichi Sankyo | 64 | |
Hiroo Sasaki | Astellas Pharma | 61 | |
Kazunori Okimura | Astellas Pharma | N/A | |
Yoshiyuki Yano | Chugai Pharmaceutical Co | N/A | |
Atsushi Kamide | Astellas Pharma | N/A | |
Iain Mackay | GlaxoSmithKline PLC ADR | 62 | |
Masahiro Ohtsuki | Daiichi Sankyo | N/A |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ann Powell, Chief Human Resource Officer, Senior Vice President | ||
Togo West, Independent Director | ||
Karen Vousden, Director | ||
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer | ||
Alan Lacy, Independent Director | ||
Robert Bertolini, Independent Director | ||
Jose Baselga, Independent Director | ||
Charles Bancroft, CFO, Executive Vice President | ||
Gerald Storch, Independent Director | ||
Louis Schmukler, President - Global Manufacturing and Supply | ||
Michael Grobstein, Independent Director | ||
Christopher Boerner, Executive Vice President and Chief Commercial Officer | ||
John Elicker, Senior Vice President - Public Affairs and Investor Relations | ||
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer | ||
Karen Santiago, Senior Vice President Controller | ||
Giovanni Caforio, COO, Director | ||
Vicki Sato, Independent Director | ||
Emmanuel Blin, Senior Vice President Chief Strategy Officer | ||
Joseph Caldarella, Senior Vice President Corporate Controller | ||
Laurie Glimcher, Independent Director | ||
Murdo Gordon, Executive Vice President Chief Commercial Officer | ||
Lamberto Andreotti, CEO, Director | ||
Thomas Lynch, Independent Director | ||
Dinesh Paliwal, Independent Director | ||
Lewis Campbell, Independent Director | ||
Theodore Samuels, Independent Director | ||
Samuel Moed, Senior Vice President - Strategic Planning and Analysis | ||
Matthew Emmens, Independent Director | ||
Ann Judge, Senior Vice President - Global Human Resources | ||
Sandra Leung, General Counsel, Corporate Secretary | ||
Paul Autenried, Senior Vice President - Enterprise Services, CIO | ||
Francis Cuss, Executive Vice President Chief Scientific Officer | ||
Paul Biondi, Senior Vice President Head - Business Development | ||
Peter Arduini, Independent Director |
Bristol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Revenue | 46.38 B | |||
EBITDA | 20.1 B | |||
Net Income | 7.01 B | |||
Cash And Equivalents | 6.07 B | |||
Cash Per Share | 3.72 X | |||
Total Debt | 39.6 B | |||
Debt To Equity | 59.40 % | |||
Current Ratio | 1.40 X | |||
Book Value Per Share | 7.55 X | |||
Cash Flow From Operations | 16.21 B |
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Ralph Lauren could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ralph Lauren when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ralph Lauren - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ralph Lauren Corp to buy it.
The correlation of Ralph Lauren is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ralph Lauren moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ralph Lauren Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ralph Lauren can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Bristol Pink Sheet
If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol Myers' history and understand the potential risks before investing.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |